Industry
Biotechnology
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
July 17, 2024 | 5:28 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 12:09 pm
Portfolio Pulse from Henry Khederian
June 24, 2024 | 8:28 pm
Portfolio Pulse from Avi Kapoor
June 24, 2024 | 5:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 3:15 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 11:49 am
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 12:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.